News|Articles|September 2, 2025

6 Hepatology Headlines You Missed in August 2025

Check out expert perspectives on semaglutide’s FDA approval for MASH and new research on PBC, infectious disease screening, and more in this August 2025 recap.

August 2025 brought a major milestone in hepatology with the FDA approval of semaglutide (Wegovy) 2.4 mg for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), based on results from the phase 3 ESSENCE trial. The decision further elevates GLP-1 receptor agonists in liver care, a focus of recent Diabetes Dialogue and Liver Lineup episodes.